BackFaron Pharmaceuticals Oy Overview

Faron Pharmaceuticals Oy Receivables

Track Faron Pharmaceuticals Oy's receivables ($200K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$201000.00

Peer trimmed avg / median

Loading

Faron Pharmaceuticals Oy Receivables History

Loading

Faron Pharmaceuticals Oy vs. peers: Receivables Comparison

Loading

Faron Pharmaceuticals Oy Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Faron Pharmaceuticals Oy (FARN.L) FAQ

Faron Pharmaceuticals Oy's receivables stands at $200K as of December 2024. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Faron Pharmaceuticals Oy reported $200K in receivables versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Faron Pharmaceuticals Oy's receivables evolved across reporting periods, while the comparison chart places FARN.L next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Faron Pharmaceuticals Oy's reading of $200K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.